GHENT, Belgium--(BUSINESS WIRE)--Confo Therapeutics, a clinical-stage company and leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced the closing of a EUR 60M Series B financing. The round was led by Ackermans & van Haaren (AvH) and included participation from additional new investors, Driehaus Capital Management and Quest for Growth (QfG), as well as existing investors, BioGeneration Ventures (BGV), Capricorn Health-tech Fund (CHF), Fund+, MINTS (University of Michigan), Perceptive Advisors, Qbic, PMV, V-Bio Ventures, VIB and Wellington Partners..

比利时根特--（商业新闻短讯）--临床阶段公司Confo Therapeutics今天宣布结束6000万欧元的B系列融资，该公司是发现靶向G蛋白偶联受体（GPCR）药物的领导者。这一轮由阿克曼和凡·哈伦（AvH）牵头，包括其他新投资者、Driehaus资本管理和追求增长（QfG）以及现有投资者、生物发电风险投资（BGV）、摩羯座健康技术基金（CHF）、基金+、MINTS（密歇根大学）、Perceptive Advisors、Qbic、PMV、V-Bio Ventures、VIB和惠灵顿合作伙伴的参与。

The proceeds will be used to advance two, wholly owned programs through Phase 1 and two additional programs to IND approval, including molecules targeting GPR75 for obesity. Confo will expand its portfolio of GPCR-targeting small molecules and therapeutic antibodies, which includes an emphasis on agonistic antibodies..

这些收益将用于推进第一阶段的两个全资项目和另外两个获得IND批准的项目，包括针对肥胖的GPR75分子。Confo将扩大其针对小分子和治疗性抗体的GPCR组合，其中包括强调激动性抗体。

“With the support from our experienced international investor syndicate, we plan to accelerate our ambitious development pipeline,” said Cedric Ververken, CEO of Confo Therapeutics. “Our plans include potential new therapies for severe rare endocrine diseases, as well as next-generation obesity drugs which could be used in combination with, or as an alternative to, GLP-1R agonists.”.

Confo Therapeutics首席执行官Cedric Ververken表示：“在我们经验丰富的国际投资者财团的支持下，我们计划加快我们雄心勃勃的发展进程。”。“我们的计划包括针对严重罕见内分泌疾病的潜在新疗法，以及可与GLP-1R激动剂联合使用或替代GLP-1R激动剂的下一代肥胖药物。”

Jeroen Vangindertael, Investment Manager at AvH added: “We have followed Confo’s development and have been repeatedly impressed with Confo’s proprietary platform and its experienced team, as well as their strategy for novel treatments in obesity and rare endocrine disorders. We are especially excited by the remarkable ease with which Confo can discover agonistic antibodies directed to GPCRs, opening up a new route to generating novel medicines.

AvH的投资经理Jeroen Vangindertael补充道：“我们一直在关注Confo的发展，并对Confo的专有平台及其经验丰富的团队以及他们针对肥胖和罕见内分泌疾病的新型治疗策略留下了深刻印象。我们特别感到兴奋的是，Confo可以非常轻松地发现针对GPCR的激动性抗体，开辟了一条产生新药的新途径。

We feel privileged to contribute to the mission of Confo Therapeutics and its exceptional management team together with this syndicate of specialist life science investors.”.

我们很荣幸能够与这一专业生命科学投资者财团一起为Confo Therapeutics及其卓越的管理团队的使命做出贡献。”

As part of the Series B financing round, Dr. Vangindertael will join Confo’s Board of Directors, and Mr. Alex Munns, Assistant Portfolio Manager at Driehaus, will be appointed as Board Observer.

作为B轮融资的一部分，Vangindertael博士将加入Confo的董事会，Driehaus的助理投资组合经理Alex Munns先生将被任命为董事会观察员。

“I am delighted to welcome our new investors and thank them for their support as we enter our next phase of development,” said Dieter Weinand, Independent Chairman of the Board of Confo Therapeutics. “In combination with the continued backing of our existing investors, the team will be able to focus on advancing these therapeutic candidates to benefit patients living with metabolic and endocrine disorders.”.

Confo Therapeutics董事会独立主席Dieter Weinand表示：“我很高兴欢迎我们的新投资者，并感谢他们在我们进入下一个发展阶段时给予的支持。”。“再加上我们现有投资者的持续支持，该团队将能够专注于推进这些候选治疗药物，使患有代谢和内分泌疾病的患者受益。”

About Confo Therapeutics

关于Confo Therapeutics

Confo Therapeutics is a clinical-stage biotechnology company committed to identifying and accelerating novel medicines targeting GPCRs (G protein-coupled receptors). It discovers small molecules and antibodies with the desired pharmacology by employing its proprietary discovery platform which uses conformation-specific ConfoBodies® to promote GPCRs into functionally relevant states.

Confo Therapeutics是一家临床阶段生物技术公司，致力于鉴定和加速靶向GPCR（G蛋白偶联受体）的新药。它通过使用其专有的发现平台发现具有所需药理学的小分子和抗体，该平台使用构象特异性ConfoBodies®将GPCR促进为功能相关状态。

Using its platform, the company is building a pipeline of product candidates to transform therapeutic outcomes for patients with a focus on metabolic and endocrine diseases. The Company’s mission is being advanced by a team of highly experienced industry experts with extensive knowledge of the discovery and development of GPCR-directed medicines.

利用其平台，该公司正在建立一系列候选产品，以改变以代谢和内分泌疾病为重点的患者的治疗结果。该公司的使命是由经验丰富的行业专家团队推进的，他们对GPCR指导药物的发现和开发具有广泛的知识。

Confo Therapeutics is headquartered in Ghent, Belgium. For more information, visit www.confotherapeutics.com.

Confo Therapeutics总部位于比利时根特。有关更多信息，请访问www.confotherapies.com。